During Thursday’s Morning trade, Shares of Real Goods Solar, Inc. (NASDAQ:RGSE), surged 16.97% to $2.20.
Real Goods Solar, has accomplished the formerly declared $5 million offering of units comprising of its Class A common stock and Series F common stock warrant at a price of $3.65 per unit.
Each unit comprised of one share of Class A common stock and a warrant to purchase 0.3 share of Class A common stock, as described in the Current Report on Form 8-K filed by the company on June 26, 2015. The warrants do not contain terms that would require the company to record derivative warrant liabilities that could reduce stockholders’ equity.
After placement agent fees and other estimated offering expenses, the net offering proceeds to RGS Energy totals about $4.4 million.
Real Goods Solar, Inc. operates as a residential and commercial solar energy engineering, procurement, and construction company in the United States. It operates in three segments: Residential, Sunetric, and Other. The company offers solar energy services, counting design, procurement, permitting, build-out, grid connection, financing referrals, and warranty and customer satisfaction.
Shares of Applied Genetic Technologies Corporation (NASDAQ:AGTC), inclined 15.84% to $18.83, during its current trading session.
Biogen (BIIB) and Applied Genetic Technologies Corporation, declared a broad partnership and license agreement to develop gene-based therapies for multiple ophthalmic diseases. The partnership will focus on the development of a portfolio of AGTC’s therapeutic programs, counting both a clinical stage candidate and a pre-clinical candidate for orphan diseases of the retina that can lead to blindness in children and adults. The agreement also comprises options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, in addition to an equity investment in AGTC by Biogen and a license agreement for manufacturing rights.
“With this collaboration, we hope to advance gene therapies to open possibilities for patients who suffer from diseases that are well understood, but have no adequate treatment,” said Olivier Danos, Ph.D., senior vice president, cell & gene therapy at Biogen. “AGTC is an exceptional partner to assist us advance our gene therapy capabilities by targeting diseases of the eye – an organ that provides an ideal setting for the localized, selective delivery of gene-based therapies.”
“We expect this partnership will further validate our novel adeno-associated virus (AAV) gene therapy platform and support the development of new therapies that may allow for transformative treatments for these rare inherited eye diseases and other clinical indications,” added Sue Washer, president and CEO of AGTC. “Biogen’s noteworthy commitment to advancing gene therapies and demonstrated success in developing innovative therapies to treat complex diseases, combined with our proprietary manufacturing technology and extensive gene therapy experience, makes this an ideal partnership.”
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes.
Finally, Aéropostale, Inc. (NYSE:ARO), gain 9.76%, and is now trading at $1.80.
Aéropostale, declared expansion plans throughout Asia with new licensing agreements in India and Indonesia. The Company plans to open stores in India through a licensing agreement with Arvind Lifestyle Brands Limited, and in Indonesia through a licensing agreement with PT Mitra Adiperkasa TBK (MAP).
Julian R. Geiger, Chief Executive Officer, stated, “India and Indonesia are two of the most populated countries in the world and see noteworthyopportunities by bringing the Aeropostale brand to these key countries. Following the successful launch of our brand in the Philippines and Singapore, we are excited to capitalize on the strong growth prospects in both India and Indonesia. We are totally comfortable partnering with two of the largest and strongest retailers in their respectful regions, Arvind Lifestyle Brands Limited and MAP.”
Aeropostale’s expansion plans in India comprise the opening of 50 standalone stores, 150 shop-in-shops in select locations, and e-commerce operations across the country over the next five years, starting in March 2016. In addition, the Company anticipates to open 10 to 12 standalone stores in Indonesia over the next five years, with its first store opening in Jakarta in Fall 2016.
Aéropostale, Inc. operates as a specialty retailer of casual apparel and accessories for 14 to 17 year-old young women and men. It operates through two segments, Retail Stores and E-Commerce, and International Licensing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
